

c) having a molecular weight of about 10 kDa to about 20k Da by reducing
SDS-PAGE,

C1 wherein the polypeptide has an amino acid sequence beginning at about amino acid
residue 247 or amino acid residue 248 from the N-terminus of CTGF, and has mitogenic and
chemotactic activity, and

wherein the antibody or antigen binding fragment thereof is not reactive with CTGF or
with platelet derived growth factor.

C2 7. (Amended) The [antibody] antigen binding fragment of claim 1, wherein the
[antibody] antigen binding fragment is an antibody fragment.

REMARKS

Claims 1 to 7 are pending. For the Examiner's convenience, a copy of the claims as they
will stand upon entry of the amendment is attached hereto as Exhibit A.

An Amendment filed in response to the final Office Action mailed March 30, 2000
(Paper No. 11). However, as indicated in the Advisory Action mailed July 13, 2000, the
Amendment was not entered. Accordingly, this Preliminary Amendment addresses issues that
were raised in the final Office Action.

A. Regarding the Amendments

Claim 1 has been amended to more clearly indicate that an antibody, or antigen binding
fragment thereof, of the invention "is not reactive with CTGF or with platelet derived growth
factor." The amendment is supported, for example, at page 14, lines 4-7, and, therefore, does not
add new matter.